Number of Shares and Voting Rights of ADOCIA as of May 31st, 2025

ADOCIA SA (Euronext Paris: ADOC) announced its total number of outstanding shares and voting rights as of May 31, 2025, reporting 18,087,690 outstanding shares, 20,213,633 theoretical voting rights, and 20,168,948 exercisable voting rights; this information is provided in compliance with French regulations regarding shareholding threshold calculations and public disclosure requirements.

Analysis

ADOCIA SA has fulfilled a regulatory obligation by disclosing its total outstanding shares and voting rights as of May 31, 2025. The company reported 18,087,690 outstanding shares, 20,213,633 theoretical voting rights, and 20,168,948 exercisable voting rights. This disclosure, mandated by the French Code de Commerce and AMF regulations, is essential for tracking shareholding threshold crossings and maintaining market transparency. The discrepancy of 44,685 between theoretical and exercisable voting rights is attributed to shares with suspended voting rights, specifically shares held by the company under a liquidity agreement. This announcement carries a neutral sentiment and a very low market impact score of 0.1, indicating it is a routine update rather than a significant market-moving event for ADOCIA. The company itself is a clinical-stage biopharmaceutical entity focused on developing innovative therapeutic solutions for diabetes and obesity, leveraging four proprietary technology platforms and holding over 25 patent families. This share capital update provides a factual data point but does not alter the underlying fundamentals or speculative nature associated with a clinical-stage biotech firm.

Key Decisions for Investors

• Investors should update their records with ADOCIA's latest share count (18,087,690) and voting rights figures (20,213,633 theoretical, 20,168,948 exercisable) as of May 31, 2025, for accurate shareholding analysis and monitoring potential threshold crossings.
• This regulatory disclosure is a standard corporate filing and does not intrinsically change ADOCIA's fundamental investment case, which remains primarily dependent on the clinical development progress of its pipeline in metabolic diseases and the value derived from its proprietary technology platforms and patent portfolio.
• Given the neutral sentiment and minimal market impact score (0.1) associated with this news, it should be interpreted as a routine transparency measure rather than a primary catalyst for immediate trading decisions; focus should remain on upcoming clinical trial results and R&D milestones for assessing long-term prospects.